Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced that Cincinnati Children’s has been activated as the seventh Qualified Treatment Center (QTC) for administering ZEVASKYN (prademagene zamikeracel), an autologous gene-modified cellular sheet therapy for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
Cincinnati Children’s, described as one of the largest epidermolysis bullosa centers in the US, can now offer ZEVASKYN to adult and pediatric RDEB patients. Abeona highlighted its Abeona Assist program, which provides personalized support for insurance, financial assistance, and travel logistics. The release also reiterates ZEVASKYN’s mechanism, indication, clinically meaningful wound healing and pain reduction after a single surgical application, and key safety information, including risks of allergic reactions, potential cancer risk, infection transmission, and common side effects such as procedural pain and itching.
Positive
- Seventh ZEVASKYN Qualified Treatment Center activated at Cincinnati Children’s, expanding U.S. treatment network
- Access infrastructure supported by Abeona Assist for insurance, financial, travel, and logistical help
Negative
- None.
News Market Reaction – ABEO
In the Jul 21 session, ABEO gained 0.77%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 01 | Employee inducement grants | Negative | -2.1% | Restricted stock awards totaling up to 9,000 shares preceded a 2.1% decline. |
| Jun 01 | Employee inducement grants | Negative | -2.6% | Restricted stock awards covering up to 13,800 shares preceded a 2.6% decline. |
| May 26 | Investor conference participation | Neutral | +0.9% | Upcoming healthcare conference participation preceded a 0.92% increase. |
| May 13 | First-quarter earnings | Positive | +0.5% | Reported $8.7 million net product revenue and cash of $168.3 million. |
| May 11 | Treatment-center activation | Positive | -0.7% | CHOP became the sixth Qualified Treatment Center, preceding a 0.68% decline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ABEO's prior access-center announcement coincided with a -0.68% move, while earnings news coincided with a 0.53% increase; recent grant notices were followed by declines.
Key Terms
autologous medical
ex vivo medical
replication-incompetent retroviral vector technical
COL7A1 medical
anaphylaxis medical
cGMP regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with Cincinnati Children’s to make ZEVASKYN available to RDEB patients in need,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona.
“As one of the centers caring for a large number of patients with RDEB, we see firsthand the profound impact this condition has on patients and their families,” said Dr. Kalyani S. Marathe, MD, MPH, Professor, UC Department of Pediatrics, UC Department of Dermatology. “We are excited to offer ZEVASKYN to our patients who have been desperate for innovations that will make their lives better. I’m proud to be a part of our EB team which has cared for this population for decades and thrilled that Cincinnati Children’s can provide this cutting-edge treatment.”
For more information about receiving ZEVASKYN treatment at Cincinnati Children’s, contact the EB Center at ebcenter@cchmc.org.
For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist®, Abeona’s comprehensive patient support program, visit www.abeonaassist.com, call 1-855-ABEONA-1 (1-855-223-6621) or email MyNavigator@AbeonaAssist.com. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.
About recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.
About ZEVASKYN® (prademagene zamikeracel) gene-modified cellular sheets
ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient’s own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com.
Indication
ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Important Safety Information
- Serious allergic reactions to ZEVASKYN can occur. Patients should get medical help right away if they experience symptoms like itching, swelling, hives, difficulty breathing, runny nose, watery eyes, or nausea. In rare cases, a severe reaction called anaphylaxis may happen.
- There is a potential risk that treatment with ZEVASKYN may contribute to the development of cancer because of how the therapy works. Patients should be monitored for the rest of their lives to check for any signs of cancer.
- ZEVASKYN is made using human and animal materials. Although these materials are tested before use, the risk of passing on infections cannot be eliminated.
- The most common side effects are pain from the procedure and itching.
This is not a complete list of side effects. Patients should call their care team for medical advice about side effects. Side effects may be reported to Abeona at 1-844-888-2236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See full Prescribing Information.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with RDEB. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our portfolio; our ability to submit an investigational new drug application for ABO-701 and enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; our ability to execute on our key business priorities; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. or other countries’ trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com